# BPC-157 + TB-500 Blend (5mg/5mg)

> A lyophilized research blend containing 5mg BPC-157 and 5mg TB-500 per vial. Review the individual compounds and blend specifications. Laboratory research use only.

- URL: https://www.22exo.com/product/bpc-157-tb-500-blend-5mg
- Price: $94.00 USD per vial (quantity pricing: 2 = 5% off, 3 = 10% off, 4 = 15% off, 5–9 = 20% off, 10+ = 25% off)
- Availability: In stock
- Category: Peptide Blends
- CAS: 137525-51-0 / 77591-33-4
- Target purity: ≥98% (COA pending)
- Formula: C62H98N16O22 / C212H350N56O78S
- Form: Lyophilized Powder
- Vial: 3 mL Multi-Dose Vial
- Certificate of analysis: pending (available on request)
- Shipping: free 2-Day Air at $200+ after discounts to eligible US street addresses; two business days in transit after dispatch. Below the threshold: $9.99 standard, 3–5 business days in transit. PO boxes and military addresses receive standard service (free at the same threshold). Typical processing: 0–1 business days.
- Intended use: in-vitro laboratory research only. Not for human or veterinary use.

## Overview

The BPC-157 + TB-500 blend combines two of the most extensively studied tissue repair peptides in a single preparation designed for synergistic wound healing and systemic regenerative research. BPC-157 (Body Protection Compound-157, 5mg) provides locally concentrated cytoprotective and angiogenic signaling through VEGF upregulation, FAK-paxillin pathway activation, and NO system modulation, while TB-500 (synthetic Thymosin Beta-4, 5mg) provides systemic reach through its unique property of distributing from the injection site to remote injury locations. Together they address tissue repair from complementary molecular angles: BPC-157 driving localized growth factor signaling and GI/tendon-specific protective mechanisms, TB-500 providing G-actin sequestration, cardiac progenitor cell activation, and systemic angiogenesis. This combination is the most commonly studied dual-peptide protocol in the tissue repair research literature.

## Mechanism

BPC-157 activates VEGF, EGF, and NGF expression and drives JAK-2/STAT-3 and FAK-paxillin signaling pathways for cell migration and wound granulation. Its modulation of the NO system provides both vascular and anti-inflammatory benefits. TB-500 simultaneously buffers G-actin via its WH2 domain to accelerate cell migration velocity, upregulates VEGF and its receptors, and activates CXCR4/SDF-1α stem cell homing. The combination produces additive VEGF upregulation through two independent pathways (BPC-157's transcriptional mechanism and TB-500's receptor-level upregulation), potentially creating synergistic angiogenic drive. TB-500's systemic distribution means the regenerative signal reaches remote injury sites simultaneously with BPC-157's locally dominant protective activity. The different cellular targets (BPC-157: endothelial cells, fibroblasts, enterocytes; TB-500: cardiomyocytes, corneal cells, neurons) create a complementary, multi-tissue repair signal.

## Published research

- BPC-157 component: Accelerated healing of transected tendons, GI mucosal protection, and neuroprotection across 100+ published studies (Sikiric et al., 1993–2018; Staresinic et al., 2003)
- TB-500 component: Significant cardiac repair with stem cell activation, angiogenesis, and corneal wound healing across multiple tissue models (Smart et al., 2007; Malinda et al., 1999)
- Combination rationale: Complementary VEGF upregulation pathways (BPC-157 through transcriptional upregulation, TB-500 through receptor sensitization) providing additive angiogenic drive
- Systemic distribution advantage: TB-500 reaches remote injury sites while BPC-157 provides localized protective signaling, creating full-system coverage from a single injection site
- The BPC-157 + TB-500 protocol is the most referenced combination in tissue repair peptide literature, with extensive anecdotal and preclinical support for its synergistic rationale

## Handling and storage

Store lyophilized blend at −20°C, protected from light. Reconstitute with bacteriostatic water. Reconstituted solution stable at 2–8°C for up to 28 days. The combination is chemically compatible: both peptides are stable in the same solution at neutral pH. Avoid repeated freeze-thaw cycles. Lyophilized form stable 24+ months at −20°C.
